Notice: This company has been marked as potentially delisted and may not be actively trading. G1 Therapeutics (GTHX) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrends G1 Therapeutics (NASDAQ:GTHX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage6.11%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$442,014.23 Get GTHX Insider Trade Alerts Want to know when executives and insiders are buying or selling G1 Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address GTHX Insider Buying and Selling by Quarter Ad Chaikin Analytics50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies. You can watch for it for free, right here. G1 Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/5/2024Andrew PerryInsiderSell1,337$2.51$3,355.87 7/5/2024John E (Jack) Jr. BaileyCEOSell7,662$2.51$19,231.62 7/5/2024John W V UmsteadCFOSell527$2.51$1,322.77 7/5/2024Terry L MurdockCOOSell2,475$2.51$6,212.25 5/23/2024Monica R ThomasInsiderSell5,826$4.27$24,877.02 3/18/2024John W V UmsteadCFOSell6,547$3.02$19,771.94 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 2/12/2024Rajesh MalikInsiderSell28,600$4.62$132,132.00 1/4/2024John W V UmsteadCFOSell111$2.94$326.34 1/4/2024Terry L MurdockCOOSell721$2.94$2,119.74 1/3/2024Rajesh MalikInsiderSell3,019$3.12$9,419.28 1/2/2024John E (Jack) Jr. BaileyCEOSell32,983$3.27$107,854.41 12/11/2023Rajesh MalikInsiderSell33,839$3.41$115,390.99 (Data available from 1/1/2013 forward) GTHX Insider Trading Activity - Frequently Asked Questions Who is on G1 Therapeutics's Insider Roster? The list of insiders at G1 Therapeutics includes Andrew Perry, James S Hanson, Jennifer K Moses, John E (Jack) Jr. Bailey, John W V Umstead, Mark A Velleca, Monica R Thomas, Rajesh Malik, and Terry L Murdock. Learn more on insiders at GTHX. What percentage of G1 Therapeutics stock is owned by insiders? 6.11% of G1 Therapeutics stock is owned by insiders. Learn more on GTHX's insider holdings. Which G1 Therapeutics insiders have been selling company stock? The following insiders have sold GTHX shares in the last 24 months: Andrew Perry ($8,801.22), Jennifer K Moses ($9,145.62), John E (Jack) Jr. Bailey ($321,058.73), John W V Umstead ($21,421.05), Monica R Thomas ($24,877.02), Rajesh Malik ($256,942.27), and Terry L Murdock ($15,610.33). How much insider selling is happening at G1 Therapeutics? Insiders have sold a total of 163,289 G1 Therapeutics shares in the last 24 months for a total of $657,856.24 sold. G1 Therapeutics Key ExecutivesMr. John E. Bailey Jr. (Age 59)CEO, President & Director Compensation: $1.06MMr. Mark Avagliano (Age 48)Chief Business Officer Compensation: $628.54kMr. John W. Umstead V (Age 39)Chief Financial Officer 1 recent tradesMr. Terry L. Murdock (Age 64)Chief Operating Officer Compensation: $541.59k1 recent tradesMr. William C. Roberts (Age 55)Vice President of Investor Relations & Corporate Communications Ms. Monica R. ThomasGeneral Counsel & Chief Compliance OfficerMr. Evan Hicks M.B.A.Vice President of MarketingDr. Rajesh K. Malik Ch.B. (Age 65)M.B., M.D., Chief Medical Officer Compensation: $596.37kMr. Andrew Perry (Age 51)Chief Commercial Officer Compensation: $568.6k1 recent tradesMr. Jeff MacdonaldSenior Director of Investor Relations & Corporate Communications More Insider Trading Tools from MarketBeat Related Companies Rigel Pharmaceuticals Insider Ownership Travere Therapeutics Insider Ownership Intellia Therapeutics Insider Ownership Spyre Therapeutics Insider Ownership Praxis Precision Medicines Insider Ownership Day One Biopharmaceuticals Insider Ownership Ocular Therapeutix Insider Ownership Syndax Pharmaceuticals Insider Ownership Arcus Biosciences Insider Ownership ARS Pharmaceuticals Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:GTHX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share G1 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GTHX Stock Alerts